证券代码：600222 证券简称：太龙药业 公告编号：临 2023-061 河南太龙药业股份有限公司 关于联合关联方共同受让产业基金份额、变更基金管理人的公告 1 / 22 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：河南京港先进制造业股权投资基金（有限合伙） （以下简称"京港基金"）。 投资金额：公司下属全资子公司杭州太龙金棠企业管理有限公 司拟以人民币219.79万元受让京港基金0.67%普通合伙份额；公司全 资子公司合计持有55%合伙份额的郑州龙华医药产业基金合伙企业 （有限合伙）拟以人民币19,096.53万元受让京港基金82.33%有限合 伙份额。 本次交易完成后，京港基金的执行事务合伙人、管理人将变更 为西藏金缘投资管理有限公司。 郑州龙华医药产业基金合伙企业（有限合伙）由公司与间接控 股股东共同控制，是公司的关联方，本次交易构成与关联方共同投资 的关联交易，但不构成重大资产重组事项。本项交易已经公司第九届 董事会第二十次会议审议通过，无需提交股东大会审议。 除本次交易外，过去12 ...

根据《中华人民共和国企业所得税法》及《高新技术企业认定管 理办法》等相关规定，公司及郑州深蓝海自通过高新技术企业认定当 年起连续三个会计年度（2023 年度至 2025 年度）可享受国家关于高 新技术企业的相关税收优惠政策，即按 15%的税率缴纳企业所得税。 关于公司及子公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，河南太龙药业股份有限公司（以下简称"公司"）根据全 国高新技术企业认定管理工作领导小组办公室发布的《对河南省认定 机构 2023 年认定报备的第一批高新技术企业进行备案的公告》文件 获悉，公司及控股子公司北京新领先医药科技发展有限公司的全资子 公司郑州深蓝海生物医药科技有限公司（以下简称"郑州深蓝海"） 顺利通过高新技术企业认定，证书编号分别为：GR202341000835、 GR202341003066。 证券代码：600222 证券简称：太龙药业 公告编号：临 2023-057 河南太龙药业股份有限公司 本次系公司及郑州深蓝海原高新技术企业证书有效期满后进行 的重新认 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-055 公司于 2023 年 12 月 1 日接到控股股东泰容产投的通知，获悉其 持有公司的部分股份被质押，具体情况如下： 1、本次股份质押基本情况 | 股东 | 是否为 | 本次质押股 | 是否为限售股 | 是否补 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | （如是，注明 | | | | 质权人 | 持股份 | 总股本 | 资资金 | | 名称 | | 数 | | 充质押 | 始日 | 期日 | | | | | | | 东 | | 限售类型） | | | | | 比例 | 比例 | 用途 | | 郑州 | | | | | | | | | | 用于为 | | | | | | | | | 中信银 | | | 收购公 | | 泰容 | | | | | 2023 | 2028 | 行股份 | | | 司 | | 产业 | | | | | 年 11 | 年 12 | | ...

被担保人名称：河南太龙药业股份有限公司（以下简称"公司" 或"上市公司"）。 本次担保金额及已实际为其提供的担保余额：公司全资子公司 桐君堂药业有限公司（以下简称"桐君堂"）为公司在中国光大银 行股份有限公司郑州如意西路支行（以下简称"光大银行郑州如意 西路支行"）最高额不超过人民币 12,000 万元的授信提供连带责任 保证；截至本公告披露日，桐君堂已实际为公司提供的担保余额为 0 元(不含本次)。 本次担保是否有反担保：无 对外担保逾期的累计数量：无 一、担保情况概述 证券代码：600222 证券简称：太龙药业 公告编号：临 2023-054 河南太龙药业股份有限公司 关于子公司为上市公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、公司名称：河南太龙药业股份有限公司 公司分别于 2023 年 4 月 6 日、2023 年 6 月 21 日召开第九届董 事会第十二次会议和 2022 年年度股东大会，审议通过了《关于公司 2023 年度向银行等金融机构申请综合授信额度的议案》，同意公司 ...

2023 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 12 单位：元 币种：人民币 项目 本报告期 本报告期 比上年同 期增减变 动幅度(%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 448,959,882.99 3.55 1,442,869,622.59 11.23 归属于上市公司股东的净利润 21,405,444.99 168.07 -16,926,351.76 70.24 归属于上市公司股东的扣除非经常 性 ...

2023 年半年度报告 重要提示 2023 年半年度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2023 年半年度报告 1 / 166 三、 本半年度报告未经审计。 四、 公司负责人尹辉、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述公司可能面临的风险，敬请投资者予以关注，具体详见本报告第 三节管理层讨论与分析之五、（一）可能面对的风险。 十一、 其他 □适用 √不适用 2 / 166 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内 ...

Group 1: Event Details - The event is scheduled for May 18, 2023, from 16:00 to 17:20 [1] - It will be held online via "全景·路演天下" platform [1] - The theme of the event is "Sincere Communication, Delivering Value" [1] Group 2: Participants - The attendees include General Manager Mr. Luo Jianchao, Board Secretary Ms. Feng Haiyan, and Financial Officer Mr. Zhao Hailin [1] - Participation may be adjusted due to special circumstances [1] Group 3: Company Commitment - The board guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The board takes legal responsibility for the truthfulness, accuracy, and completeness of the content [1]

2023 年第一季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2023 年第一季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 | | 单位：元 币种：人民币 | | | --- | --- | --- | | 项目 | 本报告期比上年同期增 本报告期 | | | | 减变动幅度(%) | | | 营业收入 | 560,317,916.01 | 32.69 | | 归属于上市公司股东的净利润 | 3,682,566.68 | 58.07 | | 归属于上市公司股东的扣除非经常性损益的净利润 | 3,452,841.10 | 40.91 | | 经营活动产生的现金流量净额 | -92,268,340.56 | 39.29 | | 基本每股收益（元/股） | 0.0065 | 58.54 | | 稀释每股收益（元/股） | 0.0065 | 58.54 | | 加权平均净资产收益率（%） | 0.23 | 0.09 | 1 / 11 2023 年第一季度报告 | 项目 | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | -- ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,960,694,309.41, representing a 22.20% increase compared to CNY 1,604,516,940.00 in 2021[20]. - The net profit attributable to shareholders of the listed company was a loss of CNY 72,140,214.59, a decrease of 1,303.26% from a profit of CNY 5,995,375.55 in 2021[20]. - The net cash flow from operating activities was a negative CNY 124,405,873.93, down 224.84% from CNY 99,655,159.11 in 2021[21]. - The total assets at the end of 2022 were CNY 3,600,184,129.95, a decrease of 4.85% from CNY 3,783,772,407.22 at the end of 2021[21]. - The net assets attributable to shareholders of the listed company decreased by 5.42% to CNY 1,570,479,281.96 from CNY 1,660,509,428.09 at the end of 2021[21]. - Basic and diluted earnings per share were both -0.1283 yuan, reflecting a significant decrease compared to 0.0107 yuan in the previous year[22]. - The weighted average return on equity was -4.31%, down from 0.37% in the previous year, indicating a decline in profitability[22]. - The gross profit margin decreased by 4.77 percentage points to 24.04% compared to the previous year[66]. - The total revenue for the year 2022 was approximately CNY 1.95 billion, with a gross margin of 24.04%, reflecting a decrease of 4.77 percentage points compared to the previous year[69]. Revenue Segments - The company's operating revenue increased by 22.20% year-on-year, with traditional Chinese medicine segment revenue growing by 29.62% and pharmaceutical formulation revenue increasing by 19.04%[22]. - The revenue from traditional Chinese medicine oral liquids increased by 19.88% year-on-year, reaching approximately CNY 514.4 million, but the gross margin decreased by 5.05 percentage points to 44.29%[69]. - The revenue from Chinese herbal pieces grew by 29.62% year-on-year, totaling approximately CNY 942.4 million, with a stable gross margin of 11.92%[69]. - The revenue from pharmaceutical research and development services remained flat, but the gross margin decreased significantly by 15.31 percentage points to 32.05% due to increased project costs[69]. - The company’s revenue from the cardiovascular system segment was 5,089.73 million RMB, with a gross margin of 83.57%, reflecting a decrease of 3.28% from the previous year[100]. - The company’s revenue from the digestive system segment was 1,473.67 million RMB, with a gross margin of 65.36%, showing a slight increase of 0.56% compared to the previous year[100]. Research and Development - The company is focusing on the development of new products and technologies, although specific details were not disclosed in the report[19]. - The company has 191 research projects, with 43 submitted for registration and 16 obtaining production registration certificates[36]. - The company launched 61 new independent research projects in 2022, with 110 projects still in the pipeline[38]. - The company reported a research and development investment of 6.36% of operating revenue, which is lower than the industry average of 10.00%[106]. - The company’s R&D investment amounted to 6,029.68 million RMB at the end of the reporting period, an increase of 4,457.21 million RMB from the beginning of the period[115]. - The company is actively pursuing the introduction of new traditional Chinese medicine products and enhancing its investment in the development of improved new drugs[23]. - The company has established partnerships with well-known universities and research institutions to enhance its research capabilities in traditional Chinese medicine[101]. Market Strategy and Competitiveness - The company plans to enhance its market competitiveness by increasing sales promotion efforts in key regions and investing in the research of classic Chinese medicine formulas[23]. - The company aims to expand its market presence and enhance customer loyalty through deeper service offerings and strategic partnerships in the pharmaceutical sector[54]. - The company is focusing on diversifying its drug research technology platforms and increasing the number of self-initiated projects, which may impact short-term profitability but is expected to yield results in the future[23]. - The company plans to expand its product range and improve brand influence through differentiated marketing strategies and academic promotion[126]. - The company is committed to strengthening its internal control systems and risk management to ensure sustainable growth[125]. Corporate Governance and Management - The company has conducted 5 shareholder meetings and 13 board meetings during the reporting period, ensuring compliance with governance standards[136]. - The company has implemented a third employee stock ownership plan to enhance performance evaluation and incentive mechanisms for management[137]. - The company has a clear organizational structure that operates independently and effectively, adhering to legal and regulatory requirements[139]. - The company has established a compensation and assessment committee under the board to oversee the remuneration of directors and senior management[153]. - The company emphasizes transparency in its remuneration practices, with clear guidelines for performance evaluation and payment schedules[153]. Environmental Responsibility - The company invested 3.22 million yuan in environmental protection during the reporting period[184]. - The company’s subsidiary, Yu Zhong Pharmaceutical Factory, was listed as a key pollutant discharge unit in Zhengzhou for 2022[185]. - The wastewater treatment facility at the company can process 1,000 tons of wastewater daily, utilizing a series of advanced treatment processes to ensure compliance with discharge standards[188]. - The company reported that all major pollutants, including SO2 and nitrogen oxides, from both its facilities met the emission standards[190]. - The company has received its pollution discharge permit as of July 2020, in compliance with national regulations[191]. Social Responsibility - Total charitable contributions amounted to 260,400 RMB, including donations to various charitable organizations and educational funds[200]. - The company donated 100,000 RMB to the Henan Charity Federation and 20,000 RMB to the Tonglu County Charity Federation[200]. - During the pandemic, the company provided anti-epidemic supplies to local communities, demonstrating its commitment to social responsibility[200].

2022 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人尹辉、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | 109,129.93 | 30,343.03 | | | 越权审批，或无正式批准文件，或偶发性的税收返还、 | | | | | 减免 | | | | | 计入当期损益的政府补助，但与公司正常经营业务密切 | | | | | 相 ...